Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR, Teijin to Codevelop Regenerative Medicine Product, Plan to Begin Clinical Studies in 2018
July 19, 2017
- Sunovion to Divest Asthma and Allergy Products to Focus on COPD
July 18, 2017
- Bayer Yakuhin to Ban Any Type of Medical Affairs Work by Sales Organization
July 18, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
- Ambicion, RIKEN Pair Up for Joint Research to Develop Novel Antiallergics
July 14, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Rejected: Nippon Chemiphar/Nagase
July 13, 2017
- Daiichi Sankyo Links Up with Max Planck Innovation, LDC on Cancer Research
July 13, 2017
- Vemlidy Counterfeit with Japanese Label Found in China
July 13, 2017
- Biogen, Univ. of Tokyo Establish Research Program on “Pharmacotherapeutics for Neuropsychiatric Disorders”
July 13, 2017
- Astellas Pursuing Corrective Measures after ABPI Suspension Extension: CEO
July 12, 2017
- Astellas Eager to Take in External Resources; Key Xtandi Data Out Later This Year
July 12, 2017
- Boehringer Ingelheim, NCC Forge Comprehensive Partnership
July 12, 2017
- Daiichi Sankyo’s Oncolytic Virus Gets Orphan Status
July 12, 2017
- Ethical Drug Sales Tick Up 1.7% in May: Crecon
July 12, 2017
- Mundipharma Inks Partnership with J1 Soccer Team, Isodine Logo Put on Uniform
July 11, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
- Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…